摘要
In the ARTEMIS-CTONG1509 multicenter phase 3 study recently published in Cancer Cell,Zhou et al.investigate the combination of the EGFR tyrosine kinase inhibitor(TKI)erlotinib and anti-angiogenic bevacizumab in treatmentnaive Chinese patients with advanced EGFR-mutant non-small cell lung cancer(NSCLC).^(1) The primary endpoint of progression-free survival(PFS)was significantly exte nded from 11.2 months with erloti nib mono therapy to 17.9 mon ths with the combination.